Event
The new adjuvant COVID-19 recombinant protein vaccine ReCOV was sequentially enhanced, and the neutralizing antibody titer against prototype strain and Omicron mutant strain BA.2 and BA.5 was significantly higher than that of mRNA vaccine. Another company developed a new adjuvant vaccine REC610 against herpes zoster virus and was approved to conduct a phase I trial with GSKShringrix as a positive control in the Philippines.
Comment
Ruike Biology has an innovative R & D platform with a new adjuvant platform as the core. The company is one of the few companies that can develop new adjuvants to match the FDA standard, has aluminum adjuvants and five FDA-approved new adjuvants for human vaccines, and continues to develop the next generation of innovative adjuvants. The company also has a protein engineering platform to provide antigen optimization solutions, an immune evaluation platform to select the best combination of antigens and adjuvants, and a mRNA vaccine platform that is the first to break through the problem of mRNA cryopreservation.
The new adjuvant COVID-19 recombinant protein vaccine ReCOV is more effective than Pfizer mRNA vaccine. ReCOV adopts NTD-RBD-Foldon trimer protein structure and a new adjuvant BFA03. The positive conversion rate of neutralizing antibody (91.5% in pilot batch, 96.0% in commercial batch) and geometric mean titer (higher than baseline: 21.4% in pilot batch, 25.1 times in commercial batch) were significantly higher than that of Pfizer Inc mRNA vaccine (positive seroconversion rate: 91.0%; geometric mean titer increased 15.7 times). The titer of neutralizing antibody against Omicron mutant BA.2 and BA.5 was also significantly higher than that of Pfizer Inc mRNA vaccine, which was only 1.4times and 1.8times lower than that of the prototype strain, respectively.
The recombinant herpes zoster vaccine REC610 has been introduced into clinic to verify the company's leading strength in the field of new adjuvant vaccine. REC610, a recombinant herpes zoster vaccine, has recently been approved to conduct a phase I clinical trial with GSK Shingrix as a positive control in the Philippines to evaluate safety and immunogenicity in healthy adults over 40 years of age. BFA01, a new adjuvant independently developed by REC610, can promote the production of VZV glycoprotein E-specific CD4+T cells and antibodies. Preclinical studies showed that the immune response induced by REC610 was not inferior to that of the control vaccine Shringrix.
Risk.
The research and development of new vaccines is not as expected; the approval and commercialization of new vaccines are not as expected.